A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Geographic Atrophy (GA)
Phase 3 – large-scale trial before approval
Conditions:
Geographic Atrophy
Sponsor: Annexon, Inc.
trial.available_in:
БГ
Overview
The primary purpose of the study is to determine if IVT injections of vonaprument every month reduce vision loss in participants with GA secondary to age-related macular degeneration (AMD).
Who can participate
Inclusion Criteria:
* Diagnosis of GA of the macula secondary to AMD as determined by the Investigator and confirmed by the independent Central Reading Center.
Exclusion Criteria:
* Geographic atrophy due to other causes than AMD such as Stargardt disease, cone-rod dystrophy, pathologic myopia, or toxic maculopathies (for example, plaquenil maculopathy) in either eye.
NOTE: Other protocol-defined inclusion and exclusion criteria may apply.
Locations
13
Australia (1)
Eye Clinic Albury Wodonga
Albury , New South Wales
Canada (1)
Calgary Retina Consultants
Calgary , Alberta
Czech Republic (1)
Fakultní nemocnice Královské Vinohrady
Prague
France (1)
Groupe Hospitalier Pellegrin - CHU de Bordeaux
Bordeaux
Germany (1)
Dietrich Bonhoeffer Klinikum Klinik für Augenheilkunde
Neubrandenburg , Mecklenburg-Vorpommern
Hungary (1)
Semmelweis Egyetem
Budapest
Italy (1)
Azienda Ospedaliera Universitaria Careggi
Florence
Netherlands (1)
Elisabeth Hospital (ETZ) - location TweeSteden ziekenhuis
БГ